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Summary In a prospective controlled clinical trial, 108 patients with pancreatic adenocarcinoma were
randomly allocated to receive tamoxifen 20 mg b.d., cyproterone acetate 100 mg t.d.s. or no active treatment.
The median survival of those receiving tamoxifen was longer than either of the other two groups (5.25
compared to 4.25 and 3 months, respectively) but this difference did not achieve statistical significance. Cox
regression analysis of 12 clinical and biochemical features showed that, for the entire group of patients,
survival was significantly longer in younger patients, those undergoing surgical bypass and those with better
initial performance status. However, even when adjustment was made to allow for the distribution of these
prognostic variables within the three groups, the difference in survival still did not achieve statistical
significance. No side-effects attributable to treatment was observed.
Carcinoma of the pancreas accounts for approximately 6,500
deaths per year in the United Kingdom, a figure exceeded
only by cancers of the lung, colon, breast and stomach
(HMSO 1986, 1988). Because of the advanced state of the
disease at presentation less than 15% of cases are amenable
to curative surgical resection (Moossa & Levin, 1981) and the
overall 5-year survival rate is currently less than 1% (Aoki &
Ogawa, 1978; Bender et al., 1982). Cytotoxic chemotherapy
has proved disappointing and while in the only controlled
trial previously carried out survival was significantly pro-
longed, side-effects were severe and no patient survived
longer than 2 years (Mallinson et al., 1980). Following the
detection of sex-hormone receptors in pancreatic carcinoma
tissue (Greenway et al., 1981; Satake et al., 1982; Sica et al.,
1984), and evidence that manipulation of the hormonal en-
vironment could influence the growth rate of these tumours
in experimental animal models (Greenway et al., 1982) there
have been a number of reports suggesting that treatment with
tamoxifen, an anti-oestrogen, may prolong survival (Theve et
al., 1983; Tonnesen & Kemp-Jensen, 1986; Wong et al.,
1987). However, the number of patients reported has been
small and in no series was there a contemporary untreated
control group. We now report a prospective randomised trial
comparing the efficacy of tamoxifen, cyproterone acetate (an
anti-androgen), and no specific treatment in 108 patients with
unresectable pancreatic adenocarcinoma.
Patients and trial design
On the basis of our previous experience the median survival
of patients with pancreatic carcinoma, from the time of
diagnosis, is in the order of 3 months. To detect a treatment
which leads to a doubling of median survival, with 95%
power, it was calculated that a minimum of 35 patients
would be required in each group. Between 1984 and 1987,
108 patients were recruited from the eight participating cen-
tres (Table I). All patients gave informed consent, and the
protocol was approved by the local ethical committees of the
participating institutions.
For recruitment into the study patients were required to
have histological or cytological confirmation of pancreatic
adenocarcinoma, or what were, in the opinion of the referr-
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ing physician, unequivocal radiological or operative findings.
Patients with ampullary carcinoma and those who had had
previous radiotherapy, cytotoxic drug therapy or resection of
the tumour were excluded. Seventy-three patients underwent
surgical bypass and 18 received a stent, placed either per-
cutaneously (16) or endoscopically (two), for relief of obs-
tructive jaundice at the discretion of the physician responsi-
ble. As soon as the diagnosis of pancreatic carcinoma was
established, or after recovery from operation, patients were
randomised to receive tamoxifen (20 mg twice daily, orally),
cyproterone acetate (100 mg t.d.s., orally) or no specific ther-
apy. No patient underwent a biliary bypass procedure after
being randomised for treatment. No attempt was made to
measure hormone receptors in tumour tissue.
On entry to the trial the following patient characteristics
(which might be related to survival time) were recorded: age,
sex, symptoms, duration of symptoms before diagnosis, stan-
dard liver function tests, site of tumour (head, body, tail),
presence or absence of metastases and Karnofsky perfor-
mance scale status (Karnofsky, 1961) (Table II). Patients
were reviewed regularly, but the efficacy of treatment was
assessed solely by survival time, no attempt being made to
assess changes in tumour size or symptoms.
Statistical methods
The distribution of the various patient characteristics be-
tween the three groups was compared and the effect of each
on patient survival was assessed by the log rank test.
Kaplan-Meier survival curves were then drawn up for both
treatment groups and compared with the control group by
the log rank test but without adjustment for the effect of
those parameters (other than treatment) which were identified
as significantly affecting survival.
Cox regression analysis (which permits simultaneous iden-
tification of multiple prognostic factors using all available
data rather than simply allowing comparison between pre-
defined groups of patients (Cox, 1972)) was then applied.
First, a stepwise method was employed, ignoring treatment
given, to generate the independent significant prognostic pat-
ient characteristics. The survival curves of the two treated
groups were then compared to that of the control group,
after appropriate adjustment for the distribution of the sig-
nificant prognostic variables between the groups. In the Cox
regression analysis first operative procedure, an unordered
patient characteristic on three levels, was represented by two
dummy variables.
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Table I Patient characteristics and presenting clinical and laboratory features in the three treatment groups
Tamoxifen Cyproterone No treatment
Number of patients (alive at time of analysis) 37 ( 5) 32 ( 2) 39 ( 2)
Mean age, years (s.d.) 65 (9.9) 63.4 (10.5) 63.8 (10.5)
Male:female 23:14 15:17 15:24
Tumour site (% head of pancreas) 29 (78) 24 (75) 32 (82)
Metastases (%) 11 (30) 9 (28) 18 (46)
Duration of symptoms less than 6 months (%) 31 (84) 26 (81) 34 (88)
Weight loss (%) 31 (84) 28 (88) 30 (77)
Abdominal pain (%) 30 (81) 24 (75) 32 (82)
Back pain (%) 20 (54) 17 (53) 22 (56)
Bilirubin>50-jmoll1 (%) 31 (84) 29 (91) 28 (72)
Alkaline phosphatase> 00 IU I-' (%) 35 (95) 30 (94) 36 ( 9)
Albumin< 35 g 1-' (%) 14 (38) 13 (41) 16 (41)
Table II Log rank tests performed for each patient characteristic to
assess effect of each on survival
Patient characteristic P value
Sex 0.84
Duration of symptoms 0.27
Jaundice 0.84
Weight loss 0.41
Abdominal pain 0.21
Tumour site 0.22
Diabetes 0.095
Metastases 0.0054*
Karnofsky score 0.0086*
First operative procedure 0.0001*
Serum bilirubin 0.16
Serum alkaline phosphatase 0.046*
Serum albumin 0.031*
* Statistically significant, P<0.05.
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Figure 1 Kaplan-Meier curves stratified by Karnofsky index.
Results
The diagnosis was established histologically in 66 (61%)
patients. In 58 tissue was obtained at the time of laparotomy
or autopsy and by various techniques in the remainder:
percutaneous fine needle biopsy (three), supraclavicular
lymph node biopsy (two) and liver biopsy of metastases
(three). Twenty patients had the diagnosis made at lapar-
otomy (without biopsy) and 22 were considered to have
unequivocal clinical and radiological (ERCP of percutaneous
cholangiography) features. There were no significant differ-
ences between the three groups in respect or any of the
patient characteristics studied (P>0.11 in all instances
(Table I)). Log rank tests showed that five characteristics had
a significant favourable effect on survival: a Karnofsky score
of greater than 50% (Figure 1), absence of detectable metas-
tases, surgical bypass procedure, an alkaline phosphatase
level of less than 400 IU 1' and an albumin concentration of
greater than 35 g I' (Table II). The subsequent regression
analysis (see below) showed that these factors were not inde-
pendent.
On life table analysis patients receiving tamoxifen had a
longer survival when compared to the control group (median
survivalsof5.25 and 3.0monthsrespectively), butthedifference
did not achieve statistical significance (unadjusted P = 0.071
(Figure 3a)). There were no apparent differences in survival
among patients receiving cyproterone acetate (median survival
4.25 months) and no active treatment (unadjusted P = 0.5)
(Figure 3b). The stepwise search using Cox regression analysis
onall subjects at the 5% level showed thatage, Karnofsky score
(Figure 1) and OP2 (the dummy variable representing the
difference between surgical biliary bypass and thestenting or no
invasiveprocedure)(Figure2),weresignificantandindependent
prognostic characteristics. After allowing for the influence of
these the significance of the difference between the treatment
groups and thecontrol group fell to P = 0.09 fortamoxifen and
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Figure 2 Kaplan-Meier curves stratified by operative proce-
dure.
to P = 0.7 for cyproterone acetate. It is also possible to derive
fromthisanalysis afigureforthe 'hazardreduction'attributable
to each ofthe significant prognostic variables, i.e. the extent to
which they account for any difference in survival between the
groups studied. The hazard reduction due to tamoxifen was
36% (95% confidence interval -7% to +62%) and due to
cyproterone 10% (95% confidence interval -52% to +47%).
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Figure 3 Kaplan-Meier curves stratified according to treatment.
(a), tamoxifen; (b), cyproterone.
No side-effects attributable to treatment with tamoxifen or
cyproterone acetate were reported and in no instance did
administration of the drugs need to be altered or stopped
because of toxicity.
Discussion
The median survival of patients with untreated pancreatic
adenocarcinomaisbetween 3 and4monthsbased onanalysisof
series involving several thousand patients (Carter et al., 1975).
Survival in ourcontemporary untreated group is in accord with
thesefigures as are those ofthe historical control groups used in
two other studies on tamoxifen treatment of pancreatic car-
cinoma. However,whereasinthese twootherstudiesthemedian
survivals of the treated patients were 7 (Tonnesen & Kemp-
Jensen, 1986) and 8.5 (Wong et al., 1987) months the com-
parable figure for ourtreated patients was 5.25 months and this
difference from the contemporary control group failed to
achievestatisticalsignificance atthe5% level. Wongetal. (1987)
reported thatprolonged survival inpatients receivingtamoxifen
appeared to be confined to post-menopausal women. Although
allthewomeninourstudywereovertheageof45andthuslikely
to be post-menopausal, we could detect no survival advantage
related to sex.
Using standard log rank analysis several factors, including
the presence ofmetastases, low Karnofsky performance score,
high alkaline phosphatase, hypoalbuminaemia and procedure
other than surgical bypass, all had an adverse effect on survival.
The log rank test, however, does not make maximum use of
continuous variables such as serum albumin - it is necessary to
compare survival in discrete groups, for example, greater and
less than 30 g 1'. Cox regression analysis (Cox, 1972), on the
other hand, permits all the available data to be used and the
determination of those variables that are independent. Using
this technique it was apparent that the only significant indepen-
dent variables were age, initial procedure and Karnofsky score.
When the entire group of patients was considered, without
takinganti-hormonal treatment intoconsideration, the survival
ofthose patients who underwent biliary bypass survival was 5.4
months, a figure almost identical to that reported in other large
series (Gudjonsson et al., 1978) and better than either drug
treatment or stenting. This presumably reflects the poorer
prognosis ofpatients with tumours ofthe body and tail (Carter
& Commis, 1975) who do not require relief of obstructive
jaundice, and the choice of a stenting procedure in poor risk
patients considered unfit for surgical bypass. Poor initial
performance status has been found to be an important adverse
prognostic factor in several other malignant and chronic
diseases.
In studies using xenografted human pancreatic carcinoma in
nude mice (Greenway et al., 1982), we found that although
cyproterone acetate and tamoxifen both significantly reduced
the rate ofgrowth there was no actual shrinkage ofthe tumour
mass. Assessment of changes in tumour size in patients with
pancreatic carcinoma is notoriously difficult. Serial ultrasound
or CT scanning are feasible but were not available in all the
participating centres, and major problems with inter-observer
variation would be expected with seven centres involved.
Although in the present study cyproterone did not have a
significant effect on survival, it has been shown that other
pharmacological agents, such as luteinising hormone-releasing
hormone (LH-RH) agonists, by leading to more profound
lowering of androgen levels are effective in hormone sensitive
tumours such as prostatic carcinoma. Indeed Redding and
Schally (1984), using chemically induced rat pancreatic tu-
mours, reported that both LH-RH agonists and surgical
castration significantly reduced tumour size. In view of these
findings and the possible marginal benefit oftamoxifen, the use
of more potent anti-androgenic agents such as the LH-RH
agonists (Gonzales-Barcena et al., 1986), perhaps in combina-
tion with tamoxifen, would appear to be worthy of study in a
clinical trial similar to that reported here.
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